In addition to these cancer types, we observed significant differences in the context of bladder cancer (EAS vs EUR and AFR vs EUR: SBS2/13 - APOBEC cytidine deaminase activity), melanoma (EAS vs EUR: SBS7a/b - ultraviolet light exposure), ovarian cancer (EAS vs EUR: SBS49 - possible sequencing artifact), head and neck cancer (AFR vs EAS: SBS87 - Thiopurine chemotherapy treatment), and breast cancer (EAS vs AFR and EAS vs EUR: SBS2/13 - APOBEC), summarized in Supp Fig 7. This evidence concerns the gene CDA and ovarian cancer.